ResearcherDongyang People's HospitalNo recent work listed

Jiangong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8067-1386; OpenAlex author ID A5102835106. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers

Papers 3

LncRNA HCP5 Regulates Pancreatic Cancer Progression by miR-140-5p/CDK8 Axis. Last author DOI 10.1089/cbr.2019.3294 ↗
Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer. Last author DOI 10.1155/2020/6073150 ↗
The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer Last author DOI 10.21203/rs.2.15310/v1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gongpan Liu · 2 shared papers, 2019–2020 · strength 0.25
- Paper Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer. DOI 10.1155/2020/6073150 ↗
- Paper The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer DOI 10.21203/rs.2.15310/v1 ↗
Xingjun Guo · 2 shared papers, 2019–2020 · strength 0.25
- Paper Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer. DOI 10.1155/2020/6073150 ↗
- Paper The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer DOI 10.21203/rs.2.15310/v1 ↗
Bo Yuan · 1 shared paper, 2020 · strength 0.13
- Paper LncRNA HCP5 Regulates Pancreatic Cancer Progression by miR-140-5p/CDK8 Axis. DOI 10.1089/cbr.2019.3294 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.